De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Betta Pharmaceuticals Toekomstige groei

Future criteriumcontroles 4/6

Betta Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 28.2% en 17.9% per jaar. De winst per aandeel zal naar verwachting groeien met 28.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.5% zijn.

Belangrijke informatie

28.2%

Groei van de winst

28.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	18.5%
Inkomstengroei	17.9%
Toekomstig rendement op eigen vermogen	10.5%
Dekking van analisten	Good
Laatst bijgewerkt	26 Aug 2024

Recente toekomstige groei-updates

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

Recent updates

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Sep 30

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Jul 30

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16

Winst- en omzetgroeiprognoses

SZSE:300558 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	4,460	849	1,980	991	6
12/31/2025	3,690	649	1,617	1,312	6
12/31/2024	3,019	486	1,278	529	6
6/30/2024	2,643	424	164	1,076	N/A
3/31/2024	2,660	395	-80	1,023	N/A
12/31/2023	2,456	348	-182	914	N/A
9/30/2023	2,757	347	-304	657	N/A
6/30/2023	2,437	199	-588	539	N/A
3/31/2023	2,324	113	-623	415	N/A
12/31/2022	2,377	145	-704	307	N/A
9/30/2022	2,184	139	-797	276	N/A
6/30/2022	2,344	263	-530	426	N/A
3/31/2022	2,212	319	-373	478	N/A
1/1/2022	2,246	383	-232	527	N/A
9/30/2021	2,087	439	-95	616	N/A
6/30/2021	2,074	678	-227	521	N/A
3/31/2021	1,842	624	-317	439	N/A
12/31/2020	1,870	606	-40	646	N/A
9/30/2020	1,818	546	-22	656	N/A
6/30/2020	1,744	287	150	671	N/A
3/31/2020	1,826	310	220	739	N/A
12/31/2019	1,554	231	-65	555	N/A
9/30/2019	1,540	218	-178	448	N/A
6/30/2019	1,405	187	-291	375	N/A
3/31/2019	1,314	176	-368	314	N/A
12/31/2018	1,224	167	-328	286	N/A
9/30/2018	1,186	202	-322	313	N/A
6/30/2018	1,110	187	-359	316	N/A
3/31/2018	1,081	225	N/A	282	N/A
12/31/2017	1,026	258	N/A	278	N/A
9/30/2017	1,016	264	N/A	276	N/A
6/30/2017	1,015	294	N/A	302	N/A
3/31/2017	990	341	N/A	355	N/A
12/31/2016	1,035	369	N/A	407	N/A
9/30/2016	987	364	N/A	400	N/A
12/31/2015	915	345	N/A	386	N/A
12/31/2014	704	271	N/A	278	N/A
12/31/2013	481	180	N/A	190	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300558 ( 28.2% per jaar) ligt boven de spaarquote ( 2.9% ).

Winst versus markt: De winst van 300558 ( 28.2% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 23.2% per jaar).

Hoge groeiwinsten: De winst van 300558 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 300558 ( 17.9% per jaar) zal naar verwachting sneller groeien dan de markt CN ( 13.2% per jaar).

Hoge groei-inkomsten: De omzet van 300558 ( 17.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300558 zal naar verwachting over 3 jaar laag zijn ( 10.5 %).

Betta Pharmaceuticals Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Recent updates

Investor sentiment deteriorates as stock falls 16%

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 33%

New minor risk - Share price stability

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

New minor risk - Earnings quality

Second quarter 2024 earnings: EPS exceeds analyst expectations

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Price target increased by 12% to CN¥65.00

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Consensus EPS estimates increase by 12%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Consensus EPS estimates fall by 13%

Price target decreased by 16% to CN¥57.04

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Price target increased by 13% to CN¥50.59

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

Price target decreased to CN¥57.39

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to CN¥117

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analysts update estimates

Price target raised to CN¥97.57

New 90-day high: CN¥120

Market pulls back on stock over the past week

New 90-day low: CN¥99.80

Analysts update estimates

Third-quarter earnings released: Revenue and earnings beat expectations